Highly active antiretroviral therapy of similar benefit for HIV-infected injection drug users

August 04, 2008

Contrary to the belief that HIV-infected injection drug users (IDUs) receive less benefit from highly active antiretroviral therapy (HAART), new research finds little difference in the survival rate between IDUs and non-IDUs after 4-5 years of receiving HAART, according to a study in the August 6 issue of JAMA, a theme issue on HIV/AIDS.

Julio S. G. Montaner, M.D., F.R.C.P.C., of the University of British Columbia and St. Paul's Hospital, Vancouver, Canada, and President-Elect, International AIDS Society, presented the findings of the study at a JAMA media briefing on HIV/AIDS.

Since the mid-1990s, substantial reductions in illness and death related to the human immunodeficiency virus (HIV) have been documented among HIV-infected persons receiving HAART. "However, a large number of prior reports have demonstrated that because of issues of social instability related to illicit drug addiction, HIV-infected IDUs may not be deriving the full benefits of HAART," the authors write. They add that other reports have shown that IDUs are less likely to be prescribed HAART and that a history of injection drug use was a predictor of worse outcome with HAART. However, long-term evaluations of HIV-treatment outcomes among IDUs in comparison with other risk groups have not been available.

Dr. Montaner and colleagues compared the rate of death between 3,116 patients with and without a history of injection drug use initiating HAART in a HIV/AIDS treatment program in British Columbia, Canada. Of the 3,116 patients, 915 were IDUs (29.4 percent). Treatment with HAART was initiated between August 1996 and June 2006. The median (midpoint) duration of follow-up was 5.3 years for IDUs and 4.3 years for non-IDUs. Patients were followed up until June 30, 2007.

During the study period 622 individuals died (20.0 percent; 232 IDUs and 390 non-IDUs). Through seven years after the initiation of HAART, the researchers found that the cumulative all-cause mortality rate was not statistically different between the 915 IDUs (26.5 percent) and 2,201 non-IDUs (21.6 percent). Further analysis also indicated similar rates of death for both groups, after adjustment for age, sex, baseline AIDS diagnosis, baseline CD4 cell count, adherence and physician experience.

"Although our findings cannot be generalized outside of [this] cohort, as efforts to improve use of HAART among IDUs expand, the fact that survival patterns were not significantly different between IDUs and non-IDUs should help to challenge the increasingly prevalent belief that IDUs may be markedly less likely to benefit from HAART. Based on these results, we conclude that HAART regimens may have effectiveness at a populational level that is not significantly different regarding the survival of individuals with and without a history of injection drug use," the authors conclude.

JAMA and Archives Journals

---

---

	HIV-ASSOCIATED METABOLIC AND MORPHOLOGIC ABNORMALITY SYNDROME: Welcome therapy may have unwelcome effects (Postgraduate Medicine) by JTE Multimedia Recently, the remarkable progress of medical science in treatment of HIV and AIDS has been found to have a price tag attached. Physicians are encountering a litany of heretofore-unrecognized metabolic abnormalities and bizarre body-composition changes in patients receiving the antiretroviral therapy that has so greatly improved their lives. In this article, Dr Cohan describes changes that have been reported and identifies potential pathophysiologic mechanisms. In addition, he offers insight into treatment of this syndrome, which is only beginning to be recognized and studied. Cohan GR. HIV-associated metabolic and morphologic abnormality syndrome: welcome therapy may have unwelcome effects. Original Publication Date: April 2000
	A Decade of HAART: The Development and Global Impact of Highly Active Antiretroviral Therapy by Josï¿1/2 M Zuniga (Editor), Alan Whiteside (Editor), Amin Ghaziani (Editor), John G Bartlett (Editor) Highly active antiretroviral therapy (HAART) is a therapeutic intervention developed by clinicians and researchers in order to fight the HIV pandemic. It has contributed to a significant reduction in AIDS-related mortality and allowed many previously bed-ridden patients to live healthier, more productive lives. Until the advent of HAART in 1996, a diagnosis of HIV infection was considered a death sentence. A decade later, the disease has been transformed into a serious, yet potentially manageable, medical condition for thousands of people living with HIV/AIDS in the developed world - almost overnight creating a generation of "HIV Survivors" - and forged a global movement to ensure that its Lazarus-like benefit reaches millions more in the developing world. This book reviews the...
	Antidepressants and Labor Market Outcomes of Persons Living with HIV: An Analysis of Users of Highly-Active Antiretroviral Therapy in the United States: 1996-2004 by Omar Galarraga (Author), David S. Salkever (Author) The work examines the effect of antidepressants on the employment of HIV-positive persons receiving highly active antiretroviral therapy (HAART). It uses U.S. panel data (1996-2004) from the Women's Interagency HIV Study (WIHS) and the Multicenter AIDS Cohort Study (MACS). Regression models of employment control for: demographic characteristics, clinical indicators, physical and mental health summary measures and local area characteristics. Instrumental variables help identify antidepressant use. The results show that antidepressant use has a positive effect on the employment probability of women living with HIV. Among women receiving HAART, and controlling for individual and local area labor market characteristics, use of antidepressants is associated with a higher probability of being...
	Combination Therapy of AIDS (Milestones in Drug Therapy) by Erik De Clercq (Editor), Anne-Mieke Vandamme (Editor) An extensive assessment of combination therapy of AIDS. Main focus is put on the Highly Active Antiretroviral Therapy (HAART) but other therapies like salvage therapy are also discussed. The chapters cover efficacy, treatment, causes of treatment failure, clinical care, guidelines, pharmacology. The volume closes with an outlook on future perspectives.
	DESIGNING SALVAGE ANTIRETROVIRAL REGIMENS: Some basic guidelines and use of resistance testing (Postgraduate Medicine1) by JTE Multimedia In the field of HIV medicine, the term "salvage regimen" refers to one that is constructed for a patient in whom multiple previous regimens have been unsuccessful, for a wide variety of reasons. Although such regimens may have unproved efficacy, they are based on some solid scientific data or principles. In this article, the authors discuss the current state of genotyping and phenotyping used for resistance testing, the challenges involved in interpreting the data they provide, and factors to keep in mind when considering a switch to a different treatment regimen. Hardy WD, Hitt RS. Designing salvage antiretroviral regimens: some basic guidelines and use of resistance testing. Original Publication Date: April 2000
	Antiretroviral Therapy by American Society Microbiolgy (Publisher)
	Models for Life: Advancing Antiretroviral Therapy in Sub-Saharan Africa--Current African Issues 31 by Jeffrey V. Lazarus (Editor), Catrine Christiansen (Editor), Lise Rosendal Ostergaard (Editor), Lisa Ann Richey (Editor) Models for Life: Advancing antiretroviral therapy in sub-Saharan Africa is based on two conferences that were held in Copenhagen and Uppsala, in September 2004. The events brought together more than 70 key actors from Denmark, Sweden, and Uganda in the field of HIV/AIDS and its treatment—antiretroviral therapy. The conferences were unique in that each panel and the subsequent discussion brought together researchers, donors, and representatives from non-governmental organizations in order to link theory, operations research, and practice. The working paper covers a wide range of the issues that were brought up at the conferences, but focuses on the following three main topics: o access to antiretroviral therapy; o H\holistic approaches to providing...
	Williams' Basic Nutrition & Diet Therapy by Staci Nix (Author) Part of the popular LPN Threads Series, Williams' Basic Nutrition & Diet Therapy is the market leader for a reason: you get coverage of hot topics, emerging trends, and cutting edge research, plus all the essentials for providing the best nutrition care. Written in a clear, conversational style, the book begins with the fundamental concepts of nutrition and then applies those concepts to diverse demographic groups in different stages of life. You also learn how selected disease processes work, and how to help communities and individuals achieve health and healthy living. A free CD contains Nutritrac, a computer program that helps you analyze case studies and create customized client profiles.An engaging design includes colorful openers, illustrations, boxes, tables, and text layout....
	INITIATING HIV THERAPY: Timing is critical, controversial A concise synopsis of recent research data and current guidelines on when to initiate antiretroviral ... and side effects. (Postgraduate Medicine) by JTE Multimedia Currently available antiretroviral drug regimens are able to suppress HIV replication and allow CD4 recovery in the vast majority of patients with HIV infection. The challenge is to match each patient to the regimen that is most likely to durably suppress HIV replication enough to prevent resistance selection without causing treatment-limiting toxicities. It is also critical, but difficult, to know when to begin treatment relative to CD4 cell count and plasma viral load. In this article, Dr Volberding addresses the central questions surrounding antiretroviral treatment initiation and reviews some available treatment options. Original Publication Date: February 2004
	In HIV therapy adherence, almost isn't good enough.(Clinical Rounds): An article from: Skin & Allergy News by Michele G. Sullivan (Author) This digital document is an article from Skin & Allergy News, published by International Medical News Group on May 1, 2005. The length of the article is 488 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: In HIV therapy adherence, almost isn't good enough.(Clinical Rounds) Author: Michele G. Sullivan Publication: Skin & Allergy News (Magazine/Journal) Date: May 1, 2005 Publisher: International Medical News Group Volume: 36 Issue: 5 Page: 44(1) Distributed by Thomson...